Mexico - Latin America Plasmid Dna Contract Manufacturing Market Size & Outlook
The plasmid dna contract manufacturing market in Mexico - Latin America is expected to reach a projected revenue of US$ 18.8 million by 2030. A compound annual growth rate of 19.1% is expected of Mexico - Latin America plasmid dna contract manufacturing market from 2024 to 2030.
Mexico plasmid dna contract manufacturing market highlights
The Mexico plasmid dna contract manufacturing market generated a revenue of USD 5.5 million in 2023 and is expected to reach USD 18.8 million by 2030.
The Mexico market is expected to grow at a CAGR of 19.1% from 2024 to 2030.
In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
Plasmid dna contract manufacturing market data book summary
Market revenue in 2023
USD 5.5 million
Market revenue in 2030
USD 18.8 million
Growth rate
19.1% (CAGR from 2023 to 2030)
Largest segment
Cell & gene therapy
Fastest growing segment
Cell & Gene Therapy
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Cell & Gene Therapy, Immunotherapy
Key market players worldwide
Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster
Other key industry trends
In terms of revenue, Mexico accounted for 1.7% of the global plasmid dna contract manufacturing market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Latin America, Brazil plasmid dna contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
Brazil is the fastest growing regional market in Latin America and is projected to reach USD 28.5 million by 2030.
Growing popularity of gene therapy, rising investments by the government, and rapid growth of biopharmaceutical industry in the country are the primary factors driving growth of the market. However, pharmaceutical & research companies are not encouraged to settle and invest in Mexico, and stringent regulations hinder the growth of the market.
Growth and innovation in the industry are priorities for the Mexican government. In particular, it has enhanced the legal & regulatory frameworks for investment firms, drug manufacturers, healthcare professionals, and patients.
As key drivers of the country's biotechnology innovation, biotech clusters, are starting to emerge in a majority of Mexican states. Moreover, Mexico has the potential to become an emerging market leader in biopharmaceutical innovation.
Mexico - Latin America Plasmid DNA Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Plasmid DNA Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell & Gene Therapy was the largest segment with a revenue share of 60.0% in 2023.
Horizon Databook has segmented the Mexico - Latin America plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Growing popularity of gene therapy, rising investments by the government, and rapid growth of biopharmaceutical industry in the country are the primary factors driving growth of the market. However, pharmaceutical & research companies are not encouraged to settle and invest in Mexico, and stringent regulations hinder the growth of the market.
Growth and innovation in the industry are priorities for the Mexican government. In particular, it has enhanced the legal & regulatory frameworks for investment firms, drug manufacturers, healthcare professionals, and patients.
As key drivers of the country's biotechnology innovation, biotech clusters, are starting to emerge in a majority of Mexican states. Moreover, Mexico has the potential to become an emerging market leader in biopharmaceutical innovation.
Mexico - Latin America Plasmid Dna Contract Manufacturing Market Application Outlook (Revenue, USD Million , 2018-2030)
Cell & Gene Therapy
Immunotherapy
Others
Mexico - Latin America Plasmid Dna Contract Manufacturing Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
Cancer
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Others
Mexico - Latin America Plasmid Dna Contract Manufacturing Market End User Outlook (Revenue, USD Million , 2018-2030)
Pharmaceutical and Biotechnology Companies
Research Institutes
Reasons to subscribe to Plasmid DNA Contract Manufacturing Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Plasmid DNA Contract Manufacturing Market Outlook databook
Our clientele includes a mix of Plasmid DNA Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico - Latin America Plasmid DNA Contract Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Mexico - Latin America Plasmid DNA Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Mexico - Latin America Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)